Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The secret appeal of Harlan Coben’s messy, addictive TV thrillers - 2Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike
- 3Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
- 4Becoming the best at Discussion: Individual Procedures
- 5Which Carrier Do You Suggest? Vote
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- 7 Delightful Ferris Wheels, Do You Like Them?
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- Finding China: Four Urban areas for a Remarkable Excursion
- Satellite observations offer insight into a tsunami's early stages
- 7 Moves toward a Sound and Dynamic Way of life
- Upgrading the Healthy benefit of Your Local Vegetables
